THALES
23.5.2022 17:17:09 CEST | Business Wire | Press release
Thales announces the new Cinterion® MV32 modem card that makes it quicker and easier for manufacturers to build and maintain resilient, high-performance 5G devices that will transform everyday life in the years ahead. Harnessing the full potential of 5G Mobile Broadband connectivity, the new modem card is designed to be at the heart of a wide array of demanding IoT (Internet of Things) use cases, such as securely connecting enterprises, remote patient care and intelligent monitoring of renewable energy generation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220522005024/en/
Effortlessly connecting 5G networks and next-gen IoT devices
The 5G roll-out will not only bring unprecedented mobile broadband speed to billions of people worldwide. It also offers an extraordinary leap in the sheer number of devices that cellular networks can support. Connectivity will be enabled for billions more machines. As a result, 5G is laying the foundations for vast new fleets of permanently connected IoT devices that enable a more sustainable and trustworthy future for us all.
Many of these new IoT devices will be highly compact. Thales’ space-saving 5G modem card therefore represents the ideal partner for the tiny embedded SIMs (eSIMs) that are another key building block for effortless connectivity. Next-generation IoT applications will demand the always-on, ultra-high speed connectivity and exceptional reliability that characterises the new Cinterion MV32 modem card:
- Extensively leverages Thales’ broad expertise in providing successful 5G IoT solutions that manage connectivity plans in the field, enabling seamless, go-anywhere 5G.
- Reliably delivers superior 5G cellular performance, thanks to industry’s most advanced and optimized radio frequency design, to enable the ultra-high speed and low latency.1
Protecting against a new wave of cyber-threats
For all its benefits, the distributed, virtualized, software-based design of many 5G networks also brings with it new vulnerabilities to cyber-attack. In response, the Cinterion MV32 5G modem card embodies Thales’ unrivalled expertise and experience in bringing robust security and protection to the 5G domain:
- Leverages Thales’ security-by-design philosophy and core expertise in robust cyber-protection – enabling dynamic protection of devices in the field and over the entire lifecycle through secure remote updates.
- Stringently and continuously penetration-tested by independent security experts.
“We were able to be a first-mover in 5G branch networking devices, in part because Thales provided a great globally-certified solution with support to a wide variety of frequency bands. They also provided responsive support to our engineers and have been a reliable supplier even when everything else is in shortage. We look forward to deploying Thales’ next-gen 5G SA MV32 into our devices in the coming year.” Keith Chau, general manager, Peplink
“For our customers, the latest generation MV32 5G modem card represents just the right product at the right time. Manufacturers worldwide must look at 5G to enable revolutionary new IoT solutions that will touch every aspect of our lives. Our new solution makes it a cinch to embed this ultra-fast connectivity. There is no trade-off between speed, latency, reliability and cyber-protection: the compact MV32 delivers them all.” Thierry Uguen, Director Product Management IoT at Thales
1 Further technical annotations :
- The new Cinterion 5G data card leverages the industry-standard M.2 form factor for easy plug-and-play as well as the latest 3GPP Release 16 enhanced Mobile Broadband (eMBB) standard for peak performance.
- It consistently supports the highest levels of data throughput without overheating as a result of its sophisticated thermal design.
- Its radio frequency design also reduces complexity and increases reliability allowing the device to tap into the highest performance grade on the field, by leveraging the latest network deployments.
To learn more, join one of our virtual launch events on May 24 at 9:00 AM or 5:00 PM.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion.
PLEASE VISIT
Thales Group
Digital Identity & Security
and Thales MV32 modem card
@Thalesgroup
View source version on businesswire.com: https://www.businesswire.com/news/home/20220522005024/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
Unpack ’26 sommerrejsetrends: Flere vælger indenlandske rejser, når de tænker mere bevidst over deres rejsevalg21.5.2026 12:35:00 CEST | Pressemeddelelse
Rejsebranchens førende databrevne trendrapport lancerer sin første sommerudgave nogensinde – Unpack ’26 Summer: The Trends in Travel I dag har Hotels.com udgivet Unpack ’26 Summer: The Trends in Travel, den nyeste udgave af virksomhedens førende trendrapport i rejsebranchen, som viser, hvordan rejseadfærd former sommerens rejsevalg. Efterspørgslen på indenlandske rejser præger sommerens ferieplanlægning. Interessen på sociale medier for indenlandske ferier er globalt steget med 77% sammenlignet med sidste år, og 44% af danske rejsende planlægger en indenlandsk rejse denne sommer*. Fra store sportsbegivenheder og koncerter til rejser inspireret af film og tv bygger Unpack ’26 Summer på indsigter fra den årlige hovedrapport Unpack ’26: The Trends in Travel™ for at fremhæve, hvor rejsende tager hen denne sommer. HHver tendens bygger på førstehåndsdata fra Hotels.com® kombineret med indsigter fra rejsende og overvågning af sociale medier. “Denne sommer bliver der stadig rejst – men på nye
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 12:30:00 CEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
Cognite and ABB Collaborate to Integrate Agentic AI into Industrial Applications to Deliver Faster Workflows21.5.2026 12:00:00 CEST | Press release
Aker BP joins as the first customer to scale agent-to-agent operations through a new generation of industrial agentic workflow applications Cognite, the leader in Industrial AI, today announced a collaboration with ABB to assess how advanced industrial AI and data capabilities can be integrated to solve key use cases in the energy sector. By adding an agentic layer to established industrial applications, including ABB Ability™ SafetyInsight™ and ABB Ability™ AlarmInsight™, using the Cognite Industrial AI and Data platform, the collaboration aims to enable "agent-to-agent" orchestration. Leading energy producer Aker BP has signed on as the first customer to implement this new generation of intelligent offerings as part of its strategy to further increase its current production efficiency of 96% and achieve a production growth target of 525,000 barrels of oil equivalent per day by 2028. Transforming Data into Actionable Business Value By breaking down traditional data silos and shifting
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts21.5.2026 12:00:00 CEST | Press release
Long-term and real-world evidence reinforce BRUKINSA as the foundation of CLL treatmentThree oral presentations at ASCO highlight rapid acceleration of BeOne’s solid tumor pipeline BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematologic malignancies and solid tumors have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago) and the 2026 European Hematology Association (EHA) Congress (June 11–14, Stockholm). Continuing to raise the bar in CLL At ASCO and EHA 2026, BeOne will showcase its hematology leadership with data spanning foundational therapies and next-generation innovation across CLL, mantle cell lymphoma and other B-cell malignancies. The data emphasize impressive long-term outcomes, durability across patient populations, and a disciplined approach to advancing future regimens. Collectively, these data undersco
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
